Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials - PubMed
3 hours ago
- #meta-analysis
- #Crohn's disease
- #biologics
- Infliximab shows effectiveness for perianal Crohn's disease in both induction and maintenance phases.
- Limited evidence supports adalimumab, ustekinumab, and upadacitinib for perianal Crohn's disease.
- Most studies are post-hoc analyses with bias; dedicated randomized controlled trials are needed.